Anticoagulation method by aprotinin administration during extracorporeal circulation and the effects on hemostasis.

Monitoring Anticoagulation During Aprotinin Utilization

The literature reviewed discussed the varying practices of anticoagulation measurement in those open heart patients receiving aprotinin. All references have reported an increase in celite ACTs (C-ACTs) in heparinized patients who were treated with aprotinin. Two authors attributed this effect to aprotinin's ability to enhance heparin's anticoagulation and therefore permit a decrease in the hepa...

HEMOSTASIS AND ANTICOAGULATION MONITORING DURING EXTRACORPOREAL MEMBRANE OXYGENATION IN CHILDREN by

Studies on cardiac lymph during extracorporeal circulation.

Cardiac lymph in dogs was used to study the metabolism and state of the myocardium during extracorporeal circulation and various additional procedures. Changes in the flow characteristics, cdor and pH of lymph were noted, and corresponding samples of cardiac lymph and coronary sinus blood were analyzed for lactate concenlmtion. Ventricular fibrillation led to higher lactate levek when compared ...

Studies on blood viscosity during extracorporeal circulation.

Blood viscosity was studied during extracorporeal circulation by means of a cone in cone viscometer. This rotational viscometer provides sixteen kinds of shear rate, ranging from 0.05 to 250.2 sec-1 • Merits and demerits of the equipment were described comparing with the capillary viscometer. In experimental study it was well demonstrated that the whole blood viscosity showed the shear rate dep...

Anticoagulation in extracorporeal circulation using recombinant hirudin: a case report.

Heparin-induced thrombocytopenia (HIT) is a severe complication following the application of heparin; antibodies against complexes of heparin and PDF4 initiate activation of platelets. This may lead to massive thrombembolism, which is associated with a slight and transient drop of platelets in HIT I or a drop below 50% after approximately 5 days in HIT II. Further administration of heparin has ...